Hoffmann-La Roche announced that on June 27, 2024, Health Canada approved Alecensaro monotherapy as an adjuvant treatment for patients with stage IB to IIIA anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) following tumor resection. This approval marks Alecensaro as the first and only ALK inhibitor available for patients with ALK-positive early-stage NSCLC who have undergone surgical tumor removal.
The company highlighted that Alecensaro demonstrated a 76% reduction in the risk of disease recurrence or death in this patient population, as evidenced by the results of the Phase III ALINA study.
